CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
CRISPR Therapeutics will webcast a September 14, 2026 fireside chat from the Morgan Stanley Global Healthcare Conference.
Rhea-AI Summary
CRISPR Therapeutics (CRSP)/b) announced that senior management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 1:05 p.m. EST.A live webcast of the fireside chat will be available on the Investors "Events & Presentations" page of the company website, with a replay accessible for 14 days after the presentation.
Positive
- None.
Negative
- None.
Details
Market Reaction – CRSP
Following this news, CRSP has declined 3.89%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $53.62. Trading volume is very high at 3.1x the average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:05 p.m. EST.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
Where can investors access the live webcast of CRISPR Therapeutics' presentation?
The live webcast will be available on the "Events & Presentations" page in the Investors section of CRISPR Therapeutics' website at https://crisprtx.gcs-web.com/events.
How long will the replay of the CRISPR Therapeutics conference presentation be available?
The replay of the webcast will be archived on the company's website for 14 days following the presentation.
When and at what time is CRISPR Therapeutics scheduled to present at the conference?
Members of CRISPR Therapeutics' senior management team are scheduled to present on Monday, September 14, 2026, at 1:05 p.m. EST.